Resident Doctors at RML Hospital Want Covishield, Not Covaxin Shots Due to 'Lack of Complete Trial'
3 years, 11 months ago

Resident Doctors at RML Hospital Want Covishield, Not Covaxin Shots Due to 'Lack of Complete Trial'

News 18  

Resident doctors at one of Delhi’s Ram Manohar Lohia Hospital on Saturday said they wanted to be administered the Serum Institute’s Covishield vaccine, instead of being given the Bharat Biotech’s Covaxin vaccine due to “apprehensions over lack of complete trial”. Covaxin, the Covid-19 vaccine produced by Hyderabad-based Bharat Biotech, is still undergoing stage-III trials. We would like to bring to your notice that the residents are a bit apprehensive about the lack of complete trial in the case of Covaxin and might not participate in huge numbers thus defeating the purpose of the vaccination,” the Resident Doctors Association of the hospital said in a a letter to the medical superintendent of the facility. The health ministry said that permission was granted for Bharat Biotech’s shot for restricted use in the “public interest as an abundant precaution in clinical trial mode, especially in the context of infection by mutant strains.” Read all the Latest News, Breaking News and Coronavirus News here

Trial Resident Doctors Vaccine Bharat Biotech Covishield Complete Trial  rml  complete  shots  covaxin  lack  doctors  vaccine  bharat  hospital  clinical  resident  trial  shot  covishield  letter  trials

History of this topic

The right way to counter a poor Covaxin safety study
4 months, 3 weeks ago

The right way to counter a poor Covaxin safety study

The Hindu  

It took all of five days for the Indian Council of Medical Research to strongly criticise the poor design of the long-term safety study of Covaxin by researchers from the Banaras Hindu University, Varanasi. A publication failure that is glaring Three years after the interim data were posted as a preprint, Bharat Biotech and ICMR are yet to publish any …

AstraZeneca's Covishield Showed Lowest Incidence of Side Effects in India Versus Globally, Says Top Govt Official
7 months, 2 weeks ago

AstraZeneca's Covishield Showed Lowest Incidence of Side Effects in India Versus Globally, Says Top Govt Official

News 18  

AstraZeneca’s vaccine has demonstrated the lowest incidence of side effects in India compared to the global average, a top government official involved in the national roll-out of Covid-19 vaccination told News18. “But only around 50 cases witnessed Thrombosis with Thrombocytopenia Syndrome — a rare side effect caused by the jab — of the 180 crore doses administered against 4 to …

After AstraZeneca covid-19 vax recall worldwide, Serum says it stopped manufacturing jabs in Dec 2021
7 months, 2 weeks ago

After AstraZeneca covid-19 vax recall worldwide, Serum says it stopped manufacturing jabs in Dec 2021

Live Mint  

New Delhi: The Serum Institute of India on Wednesday said it has stopped making and supplying covid-19 vaccine Covishield after AstraZeneca, the British drugmaker that helped develop the vaccine, announced it too was withdrawing its version of the jab worldwide. The development follows the launch of a class action suit in the UK over allegations that the UK vaccine caused …

Stopped manufacturing Covishield since December 2021, says Serum Institute
7 months, 2 weeks ago

Stopped manufacturing Covishield since December 2021, says Serum Institute

Hindustan Times  

Pune-based Serum Institute of India stopped manufacturing its anti-Covid-19 vaccine Covishield in 2021, according to a statement issued by the company on Wednesday after British-Swedish pharmaceutical manufacturer AstraZeneca announced it was withdrawing its vaccine against Covid, Vaxzevria, due to “commercial reasons” as demand for it decreased globally. Consequently, since December 2021, we have stopped the manufacturing and supply of additional …

As AstraZeneca announces vaccine withdrawal, Serum Institute says stopped Covishield in 2021
7 months, 2 weeks ago

As AstraZeneca announces vaccine withdrawal, Serum Institute says stopped Covishield in 2021

New Indian Express  

NEW DELHI: Days after AstraZeneca admitted for the first time in court documents that their Covid-19 vaccine can cause a rare and dangerous side effect, the British pharma giant announced that they are withdrawing it globally. In its statement, AstraZeneca said, "As multiple, variant COVID-19 vaccines have since been developed, there is a surplus of available updated vaccines. According to …

Covishield vaccine has had more benefits than risks, says study by Kozhikode doctors
7 months, 2 weeks ago

Covishield vaccine has had more benefits than risks, says study by Kozhikode doctors

The Hindu  

At a time when the safety aspects of the Covishield vaccine have kicked up a row, a retrospective study by two doctors from Kozhikode has claimed that its risks are minimal in view of the benefits. The controversy arose after pharmaceutical company AstraZeneca admitted in the High Court of London, United Kingdom, that its vaccine against COVID-19 had the potential …

‘Safety is primary focus’: Covaxin-developer amid reports on AstraZeneca vaccine
7 months, 3 weeks ago

‘Safety is primary focus’: Covaxin-developer amid reports on AstraZeneca vaccine

Hindustan Times  

Amid reports over potential rare side effects of the AstraZeneca-Oxford COVID-19 vaccine, Bharat Biotech, which developed the Covaxin, said in a statement that the vaccine was developed with a "single-minded focus on safety first." It stated that Covaxin was the "only Covid vaccine" in government of India's COVID-19 immunisation program to have conducted efficacy trials in India. "@bharatbiotech announcement - …

Covishield | Plea in Supreme Court for probe panel for vaccine’s ‘risk factors’
7 months, 3 weeks ago

Covishield | Plea in Supreme Court for probe panel for vaccine’s ‘risk factors’

The Hindu  

The controversy over the safety aspects of the Covishield vaccine reached the Supreme Court on Wednesday, May 1, 2024, with a petition seeking the constitution of an expert medical panel to study the risk factors. Now after the document filed in UK court by the developer of Covishield, we are compelled to think on the risk and hazardous consequences of …

Covishield more effective than Covaxin: Study
9 months, 2 weeks ago

Covishield more effective than Covaxin: Study

New Indian Express  

BENGALURU: Covishield vaccine had higher antibody response compared to Covaxin during the pandemic, according to a study by a consortium of 11 institutions led by scientists from the National Centre for Biological Sciences, Bengaluru. In all, 691 people aged between 18 and 45, mostly from Bengaluru and Pune, were part of the study.’Immunogenicity of SARS - CoV-2 vaccines Covaxin and …

What study on Covishield versus Covaxin vaccine reveals
9 months, 2 weeks ago

What study on Covishield versus Covaxin vaccine reveals

The Hindu  

March 07, 2024 10:59 am | Updated March 09, 2024 10:53 am IST - Bengaluru A new study by a consortium of 11 institutes, led by scientists from the National Centre for Biological Sciences, has found that the Covishield vaccine demonstrated more robust immune responses compared to Covaxin. The key findings state that Covishield, leveraging a virus vector to deliver …

Serum Institute of India to produce 5mn Covishield doses in two months
1 year, 8 months ago

Serum Institute of India to produce 5mn Covishield doses in two months

Hindustan Times  

Serum Institute of India chief executive officer Adar Poonawalla, while underlining that the current strain of Covid is mild and the demand for vaccine shots is low, said his firm will produce five to six million Covishield doses in the next two to three months and same amount of stock is already available for Covovax. According to Poonawalla, SII has …

Serum Institute could resume Covishield production as Covid cases rise
1 year, 8 months ago

Serum Institute could resume Covishield production as Covid cases rise

Live Mint  

The Serum Institute of India could resume production of the Covishield Covid-19 vaccine as infections rise in the country, a company spokesperson said on Wednesday. Dr Amitav Banerjee - an epidemiologist who leads DY Patil Medical College in Pune has earlier said that Covishield carried a ‘double whammy of risk’. Many would perhaps not know that Covishield carries a DNA …

Amid Covid surge, Tricity short of vaccine doses
1 year, 8 months ago

Amid Covid surge, Tricity short of vaccine doses

Hindustan Times  

Amid a surge in Covid infections, the Tricity is facing a glaring lack of vaccine availability. Director, health services, Dr Suman Singh has confirmed that the Covid-19 vaccine is currently unavailable, and the department has already communicated this to the Government of India for additional supplies. According to data provided by the health department, a total of 10,89,773 first doses …

’Covishield shouldn’t have been rolled out’: Doctor flags ’severe’ side-effects
1 year, 10 months ago

’Covishield shouldn’t have been rolled out’: Doctor flags ’severe’ side-effects

Live Mint  

A well known British-Indian cardiologist has flagged the cardiovascular side effects of the Covishield vaccine. According to Dr Aseem Malhotra, the vaccine manufactured in India by the Serum Institute is ‘even worse’ than mRNA COVID-19 vaccines when it came to concerns such as heart attacks and strokes. Citing a comparison published in a peer-reviewed journal, he said that the Oxford-AstraZeneca …

Not Permissible To Take One Dose Of Covishield And Another Of Covaxin: Centre To Delhi High Court
1 year, 10 months ago

Not Permissible To Take One Dose Of Covishield And Another Of Covaxin: Centre To Delhi High Court

Live Law  

The Central Government has informed the Delhi High Court that it is not permissible for an individual to take first dose of Covishield and second dose of Covaxin. Central Government’s standing counsel Anurag Ahluwalia told Justice Prathiba M Singh that mixing of two COVID-19 vaccines is not permissible for the first and second dose. The court was hearing a plea …

DCGI Approves Market Authorisation for SII's Covid Vaccine Covovax as Heterologous Booster Dose
1 year, 11 months ago

DCGI Approves Market Authorisation for SII's Covid Vaccine Covovax as Heterologous Booster Dose

News 18  

The Drug Controller General of India has approved market authorisation to COVID-19 vaccine Covovax as a heterologous booster dose for adults who have been administered two doses of Covishield or Covaxin, official sources said on Monday. Prakash Kumar Singh, Director of Government and Regulatory Affairs at the Serum Institute of India, had recently written to the DCGI for the approval …

COVID-19: Covovax vaccine to get approval as booster dose in 10-15 days, says Poonawalla
1 year, 11 months ago

COVID-19: Covovax vaccine to get approval as booster dose in 10-15 days, says Poonawalla

Firstpost  

Pune: Chief Executive Officer of Serum Institute of India, Adar Poonawalla, has said their Covovax vaccine will get approval as a booster dose against Covid-19 in the next 10 to 15 days. Poonawalla told the media that the vaccine works very well against the Omicron variant of coronavirus. Speaking to reporters on the sidelines of an event at the Bharati …

Covovax more efficient than Covishield against new variant: Poonawalla
1 year, 11 months ago

Covovax more efficient than Covishield against new variant: Poonawalla

Hindustan Times  

Adar Poonawalla, Chief executive Officer at Serum Institute of India said Covovax has better efficacy than the Covishield vaccine against the new covid variant. NCP chief Sharad Pawar, Deputy Chief Minister Devendra and Adar Poonawalla at the Inauguration Bharti Vidyapeeth Super Speciality Hospita at Bharti Vidyapeeth, Katraj on Sunday. And we are hopeful that the permission will be granted soon …

Covishield Immune Responses Against Covid Variants Higher Than Covaxin: Study
1 year, 11 months ago

Covishield Immune Responses Against Covid Variants Higher Than Covaxin: Study

News 18  

Neutralising antibody responses against the SARS-COV-2 virus and its variants of concern are higher among Covishield recipients than those who took the indigenously made Covaxin, according to a multi-centre study. Covishield elicited immune responses of higher magnitude and breadth than Covaxin in both seronegative individuals and seropositive individuals, across cohorts representing the pre-vaccination immune history of the majority of the …

Covid: 250 million Corbevax, Covaxin in stock, ready for dispatch
1 year, 11 months ago

Covid: 250 million Corbevax, Covaxin in stock, ready for dispatch

Hindustan Times  

Around 250 million Covid vaccines manufactured by two major Hyderabad-based units – Biological E and Bharat Biotech – are ready for dispatch in the market as soon as orders are received. Nearly 200 million Corbevax vaccine of Biological E and 50 million of Bharat Biotech's Covaxin are stockpiled at the moment. Read| Covid drills at hospitals; case count remains low …

Biological E, Bharat Biotech Together Sitting on Stockpile of 250 Million Covid Vaccine Doses
1 year, 11 months ago

Biological E, Bharat Biotech Together Sitting on Stockpile of 250 Million Covid Vaccine Doses

News 18  

Two major vaccine makers from Hyderabad, Biological E Ltd and Bharat Biotech, together are holding about 250 million doses of Covid-19 vaccines ready to dispatch as and when orders are received. According to respective company sources, Biological E is holding 200 million doses of its Covid-19 vaccine Corbevax while Bharat Biotech is sitting on a stockpile of 50 million doses …

Biological E, Bharat Biotech have stockpile of 250 million COVID vaccine doses
1 year, 11 months ago

Biological E, Bharat Biotech have stockpile of 250 million COVID vaccine doses

India TV News  

As Covid cases are increasing in the country, now focus is back on vaccination drive. According to sources- two major vaccine makers from Hyderabad, Biological E Ltd and Bharat Biotech, together have about 250 million doses of COVID-19 vaccines ready to dispatch as and when orders are received. Corbevax and Covaxin stocks Biological E held 200 million doses of its …

Nasal vaccines to roll out in private hospitals soon
2 years ago

Nasal vaccines to roll out in private hospitals soon

Hindustan Times  

A new coronavirus vaccine used as a nasal spray will only be available at private health facilities and the Co-WIN platform was set to be tweaked on Friday to allow people to immediately begin booking shots, people aware of the matter said on Friday. On Thursday, India’s technical expert committee on immunization— National Technical Advisory Group on Immunisation —recommended the …

90L in city yet to get booster shot, but BMC has only 6K Covaxin doses
2 years ago

90L in city yet to get booster shot, but BMC has only 6K Covaxin doses

Hindustan Times  

Even as the country is bracing up for a possible surge in Covid-19 cases, the Brihanmumbai Municipal Corporation has only 6,000 Covaxin doses left while there have been no stocks of Covishield or Corbevax for the last few months. BMC’s executive health officer Dr Mangala Gomare said only 16% of the eligible population have received the booster dose and around …

Bharat Biotech’s nasal vaccine to be available as booster dose
2 years ago

Bharat Biotech’s nasal vaccine to be available as booster dose

The Hindu  

With the threat of COVID-19 resurfacing and India ramping up preventive health surveillance measures, Health Minister Mansukh Mandaviya said on Friday that a vaccine, which could be administered as nasal drops, would henceforth be available for public use. “We have made available a nasal vaccine, developed by Bharat Biotech, that can be used as a precaution dose. A spokesperson for …

Bharat Biotech urges Centre to include its intranasal COVID vaccine in CoWIN portal
2 years ago

Bharat Biotech urges Centre to include its intranasal COVID vaccine in CoWIN portal

Deccan Chronicle  

Hyderabad: Bharat Biotech has requested the central government to include its intranasal COVID-19 vaccine iNCOVACC, in CoWIN portal to enable the recipients of the jab to get vaccination certificate. The company sources said Bharat Biotech is currently holding discussions with international “potential partners” who have approached the company for manufacturing and distribution of the intranasal vaccine globally. “Since iNCOVACC has …

Bharat Biotech misstated Covaxin trial data
2 years ago

Bharat Biotech misstated Covaxin trial data

Deccan Chronicle  

HYDERABAD: Extremely serious procedural leniencies and incorrect reporting of the results of trials of Covaxin, Bharat Biotech’s anti-Covid vaccine, have come to light, raising some very uncomfortable questions on the vaccine’s rollout for general use in India. Inquiries and investigation into the three phases of human trials of Covaxin have found grave reporting errors – some that appear to be …

50 million doses of Covaxin set to expire early 2023 due to poor offtake
2 years, 1 month ago

50 million doses of Covaxin set to expire early 2023 due to poor offtake

The Hindu  

Nearly 50 million doses of Bharat Biotech’s COVID-19 vaccine, Covaxin lying with the firm are set to expire early next year as there are no takers owing to poor demand, company sources said. Due to lack of product demand, production stoppage of Covaxin - a two dose jab, was initiated by Bharat Biotech earlier this year, though the vaccine maker …

COVID: 50 million Covaxin doses set to expire early 2023 due to poor off take
2 years, 1 month ago

COVID: 50 million Covaxin doses set to expire early 2023 due to poor off take

India TV News  

Highlights Covaxin lying with the firm are set to expire early next year There are no takers owing to poor demand, said company sources India reported 1,082 fresh COVID-19 cases on Saturday Covaxin news: Nearly 50 million doses of Bharat Biotech’s COVID-19 vaccine, Covaxin lying with the firm are set to expire early next year as there are no takers …

SII stopped Covishield production last year; says Adar Poonawalla; claims nearly 100 million doses expired
2 years, 2 months ago

SII stopped Covishield production last year; says Adar Poonawalla; claims nearly 100 million doses expired

India TV News  

Highlights Adar Poonawalla said SII halted the production of vaccines in December 2021 Booster vaccines have no demand, Adar Poonawalla said There is general lethargy among people and they are fed up with the pandemic, Poonawalla said Serum Institute of India has stopped the production of the Covishield vaccine as there are not many takers for COVID-19 booster doses. The …

COVID-19: Corbevax to be given as boosters at vaccination centres from today
2 years, 4 months ago

COVID-19: Corbevax to be given as boosters at vaccination centres from today

Live Mint  

Hyderabad based-Biological E Ltd 's recently approved heterologous Covid-19 vaccine Corbevax to be available as a booster dose on the COWIN App in both public and private vaccination centres from 12 August, the firm said on 11 August. The Union Health Ministry approved Corbevax as India's first heterologous COVID-19 booster shot for 18 years and above after the six months …

Corbevax as Covid booster for adults from August 12. Check details
2 years, 4 months ago

Corbevax as Covid booster for adults from August 12. Check details

India Today  

In a boost to India’s fight against coronavirus, the government gave nod to Biological E's Corbevax as a precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin. Announcing the decision, Union Health minister Mansukh Mandaviya said, “Further Strengthening India's arsenal against Covid-19, Ministry of Health and Family Welfare approves Corbevax as precaution dose for those …

Corbevax approved as precaution dose for adults vaccinated with Covaxin, Covishield
2 years, 4 months ago

Corbevax approved as precaution dose for adults vaccinated with Covaxin, Covishield

Deccan Chronicle  

New Delhi: The government has approved Biological E's Corbevax as a precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin, official sources said on Wednesday. "Corbevax will be considered as a precaution dose after completion of six months or 26 weeks from the date of administration of the second dose of either Covaxin or Covishield …

Corbevax approved as booster for those jabbed with Covishield, Covaxin: Report
2 years, 4 months ago

Corbevax approved as booster for those jabbed with Covishield, Covaxin: Report

Live Mint  

The government has approved Biological E's Corbevax as a precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin, news agency PTI has reported on 10 August citing official sources. "Corbevax will be considered as a precaution dose after completion of six months or 26 weeks from the date of administration of the second dose of …

Corbevax approved as precaution dose for adults vaccinated with Covaxin, Covishield
2 years, 4 months ago

Corbevax approved as precaution dose for adults vaccinated with Covaxin, Covishield

India Today  

The government has approved Biological E's Corbevax as a precautionary dose for those above 18 years fully vaccinated with either Covishield or Covaxin, official sources said on Wednesday. "Corbevax will be considered as a precautionary dose after completion of six months or 26 weeks from the date of administration of the second dose of either Covaxin or Covishield vaccines for …

In A First, Biological E's Corbevax Approved As Covid Booster for Covishield, Covaxin Recipients
2 years, 4 months ago

In A First, Biological E's Corbevax Approved As Covid Booster for Covishield, Covaxin Recipients

News 18  

The Centre has approved Biological E’s Corbevax as a Covid-19 precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin. Union Health Secretary Rajesh Bhushan said, “Corbevax will be available as precaution dose after completion of six months or 26 weeks from the date of administration of the second dose of either Covaxin or Covishield vaccines …

Corbevax approved as precaution dose for adults vaccinated with Covaxin, Covishield
2 years, 4 months ago

Corbevax approved as precaution dose for adults vaccinated with Covaxin, Covishield

India TV News  

Highlights Biological E's Corbevax has been approved as a booster or precaution dose. Covid vaccination: Biological E's Corbevax has been approved as a booster or precaution dose for those above the age of 18, and those who are fully vaccinated with either Covishield or Covaxin. "Corbevax will be considered as a precaution dose after completion of six months or 26 …

Govt Nod for Corbevax as Booster for Adults Vaccinated with Covishield, Covaxin Soon
2 years, 4 months ago

Govt Nod for Corbevax as Booster for Adults Vaccinated with Covishield, Covaxin Soon

News 18  

The Union health ministry is expected to soon approve Biological E’s Corbevax as a precaution dose for people above 18 years who are double vaccinated with either Covishield or Covaxin, official sources said on Tuesday. “Corbevax will be considered as a precaution dose after completion of 6 months or 26 weeks from the date of administration of the second dose …

Adults may get different vaccine as booster shot instead of Covishield, Covaxin
2 years, 4 months ago

Adults may get different vaccine as booster shot instead of Covishield, Covaxin

Live Mint  

As the government has continued to emphasize Covid booster doses due to the rising number of cases, a panel has recommended a different vaccine for Indian adults. Government panel National Technical Advisory Group on Immunisation has recommended Biological E's Corbevax as a precaution dose for adults fully vaccinated with either Covishield or Covaxin. "Corbevax may be considered for a third/precaution …

India's Covid Vaccinations Hit 200 Crore Mark in Big Milestone for 7-Phase Drive Under Modi's Leadership
2 years, 5 months ago

India's Covid Vaccinations Hit 200 Crore Mark in Big Milestone for 7-Phase Drive Under Modi's Leadership

News 18  

India has crossed record 200 crore mark in Covid-19 vaccinations within 18 months of launching the inoculation exercise in January last year. #200CroreVaccinations https://t.co/FtobFYBprV— Dr Mansukh Mandaviya July 17, 2022 A seven-phase vaccination drive was followed on the principle of Prioritization for Vaccine Administration based on scientific advice and global best practices, government officials told News18. While some experts had …

Allowing Corbevax as booster for those vaccinated with Coivishield, Covaxin likely to be considered by NTAGI
2 years, 5 months ago

Allowing Corbevax as booster for those vaccinated with Coivishield, Covaxin likely to be considered by NTAGI

The Hindu  

Allowing Biological E’s Corbevax as a booster for those fully vaccinated against COVID-19 with either Covishield or Covaxin is likely to be considered by the NTAGI, which is scheduled to meet on Tuesday, sources said. “The National Technical Advisory Group on Immunisation will discuss allowing Corbevax, which has been cleared by the DCGI, as a booster for those fully vaccinated …

NTAGI to Review Covaxin, Corbevax Data for 6-12 Yrs Thursday, Discuss Reducing Booster Dose Gap
2 years, 6 months ago

NTAGI to Review Covaxin, Corbevax Data for 6-12 Yrs Thursday, Discuss Reducing Booster Dose Gap

News 18  

Government advisory panel NTAGI will meet on Thursday to review data on Covaxin and Corbevax vaccines for the 6-12 age group and also deliberate on reducing the gap between the second and precaution doses from the current nine to six months. The agenda for the NTAGI's Standing Technical Sub-Committee meeting includes a discussion on a study by the CMC Vellore …

Corbevax gets DCGI nod as COVID-19 booster after two doses of Covishield or Covaxin
2 years, 6 months ago

Corbevax gets DCGI nod as COVID-19 booster after two doses of Covishield or Covaxin

The Hindu  

Hyderabad-based Biological E. Limited ’s COVID-19 vaccine Corbevax has been approved by the Drug Controller General of India as a heterologous COVID-19 booster dose to individuals aged 18 years and above after 6 months of administration of primary vaccination of Covaxin or Covishield vaccines for restricted use in emergency situations. ‘’Recently, BE furnished its clinical trials data to the DCGI, …

Corbevax Gets DCGI Approval As Covid-19 Vaccine Booster Dose For 18 Years And Above
2 years, 6 months ago

Corbevax Gets DCGI Approval As Covid-19 Vaccine Booster Dose For 18 Years And Above

ABP News  

New Delhi: The Drug Controller General of India approved the Corbevax Covid-19 booster as heterologous Covid-19 booster dose for adults above the age of 18 years who got their primary Covid-19 vaccination of Covishield or Covaxin administered six months before, reported news agency ANI. Recently, BE has furnished its clinical trials data to the DCGI who after a detailed evaluation …

Germany recognises Bharat Biotech's Covaxin for travel from June 1
2 years, 6 months ago

Germany recognises Bharat Biotech's Covaxin for travel from June 1

India TV News  

Highlights WHO in November last year issued an emergency use listing for Covaxin The step added a growing portfolio of vaccines validated for the prevention of COVID-19 WHO's EUL procedure assesses the quality, safety and efficacy of COVID-19 vaccines Germany has recognised the WHO-listed Bharat Biotech's COVID vaccine Covaxin, for travel to the country starting June 1. World Health Organization …

Mix and match of Covid vaccine for booster shots unlikely to be allowed: Report
2 years, 7 months ago

Mix and match of Covid vaccine for booster shots unlikely to be allowed: Report

Live Mint  

The government may not allow the administration of a precaution Covid-19 dose that is different from the one used for primary vaccination, reported news agency PTI, quoting sources, on Thursday. This comes in light of a recent study by the Christian Medical College Vellore, which showed that a booster dose of Covishield after primary vaccination with Covaxin gives 6 to …

Biological E seeks EUA of Corbevax as booster for Covishield, Covaxin recipients
2 years, 7 months ago

Biological E seeks EUA of Corbevax as booster for Covishield, Covaxin recipients

Live Mint  

Hyderabad-based Biological E has submitted an application to India's drug regulator, seeking emergency use authorisation for its Covid-19 vaccine Corbevax as a booster dose for adults who have been given two doses of either Covishield or Covaxin, reported news agency PTI, quoting sources. “We are now submitting the marketing authorization application for grant of permission Corbevax for restricted use in …

No Haste In Granting Emergency Use Authorization To Covaxin & Covishield: Supreme Court
2 years, 7 months ago

No Haste In Granting Emergency Use Authorization To Covaxin & Covishield: Supreme Court

Live Law  

In its judgment holding that the policy of the Union Government on COVID-19 vaccination policy is reasonable, the Supreme Court rejected the contention that restricted emergency use approvals had been granted to COVISHIELD and COVAXIN in haste, without thorough review of the relevant data.The court observed that the challenge to the procedures adopted by the expertbodies while granting. "However, it …

Govt panel approves use of Corbevax for 5-12 year age group
2 years, 8 months ago

Govt panel approves use of Corbevax for 5-12 year age group

India Today  

Expert panel of Drug Controller General of India -- India’s drug regulator-- has recommended granting emergency use authorisation for Biological E's Covid-19 vaccine Corbevax for children in 5 to 12 years age group. "The Subject Expert Committee on COVID-19 of the CDSCO which deliberated on Biological E's EUA application has recommended granting emergency use authorisation for use of Corbevax in …

Centre’s decision on mix-and-match boosters likely in two weeks: Official
2 years, 8 months ago

Centre’s decision on mix-and-match boosters likely in two weeks: Official

Hindustan Times  

The government may be able to decide in two weeks whether to mix and match the booster doses of approved Covid-19 vaccines based on India-specific trial data being prepared by the Christian Medical College in Vellore, according to people familiar with the development. CMC Vellore, which was permitted to conduct homologous as well as heterologous booster dose trial by the …

Discover Related